Asuka Morizane
Kyoto University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Asuka Morizane.
Journal of Clinical Investigation | 2005
Yasushi Takagi; Jun Takahashi; Hidemoto Saiki; Asuka Morizane; Takuya Hayashi; Yo Kishi; Hitoshi Fukuda; Yo Okamoto; Masaomi Koyanagi; Makoto Ideguchi; Hideki Hayashi; Takayuki Imazato; Hiroshi Kawasaki; Hirofumi Suemori; Shigeki Omachi; Hidehiko Iida; Nobuyuki Itoh; Norio Nakatsuji; Yoshiki Sasai; Nobuo Hashimoto
Parkinson disease (PD) is a neurodegenerative disorder characterized by loss of midbrain dopaminergic (DA) neurons. ES cells are currently the most promising donor cell source for cell-replacement therapy in PD. We previously described a strong neuralizing activity present on the surface of stromal cells, named stromal cell-derived inducing activity (SDIA). In this study, we generated neurospheres composed of neural progenitors from monkey ES cells, which are capable of producing large numbers of DA neurons. We demonstrated that FGF20, preferentially expressed in the substantia nigra, acts synergistically with FGF2 to increase the number of DA neurons in ES cell-derived neurospheres. We also analyzed the effect of transplantation of DA neurons generated from monkey ES cells into 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated (MPTP-treated) monkeys, a primate model for PD. Behavioral studies and functional imaging revealed that the transplanted cells functioned as DA neurons and attenuated MPTP-induced neurological symptoms.
Stem Cells | 2006
Anke Brederlau; Ana Sofia Correia; Sergey V. Anisimov; Muna Elmi; Gesine Paul; Laurent Roybon; Asuka Morizane; Filip Bergquist; Ilse Riebe; Ulf Nannmark; Manolo Carta; Erik Hanse; Jun Takahashi; Yoshiki Sasai; Keiko Funa; P. Brundin; Peter Eriksson; Jia-Yi Li
Human embryonic stem cells (hESCs) have been proposed as a source of dopamine (DA) neurons for transplantation in Parkinsons disease (PD). We have investigated the effect of in vitro predifferentiation on in vivo survival and differentiation of hESCs implanted into the 6‐OHDA (6‐hydroxydopamine)‐lesion rat model of PD. The hESCs were cocultured with PA6 cells for 16, 20, or 23 days, leading to the in vitro differentiation into DA neurons. Grafted hESC‐derived cells survived well and expressed neuronal markers. However, very few exhibited a DA neuron phenotype. Reversal of lesion‐induced motor deficits was not observed. Rats grafted with hESCs predifferentiated in vitro for 16 days developed severe teratomas, whereas most rats grafted with hESCs predifferentiated for 20 and 23 days remained healthy until the end of the experiment. This indicates that prolonged in vitro differentiation of hESCs is essential for preventing formation of teratomas.
Science Translational Medicine | 2012
Naohiro Egawa; Shiho Kitaoka; Kayoko Tsukita; Motoko Naitoh; Kazutoshi Takahashi; Takuya Yamamoto; Fumihiko Adachi; Takayuki Kondo; Keisuke Okita; Isao Asaka; Takashi Aoi; Akira Watanabe; Yasuhiro Yamada; Asuka Morizane; Jun Takahashi; Takashi Ayaki; Hidefumi Ito; Katsuhiro Yoshikawa; Satoko Yamawaki; Shigehiko Suzuki; Dai Watanabe; Hiroyuki Hioki; Takeshi Kaneko; Kouki Makioka; Koichi Okamoto; Hiroshi Takuma; Akira Tamaoka; Kazuko Hasegawa; Takashi Nonaka; Masato Hasegawa
Anacardic acid attenuates mutant TDP-43–associated abnormalities in motor neurons derived from ALS patient–specific induced pluripotent stem cells. A Stepping Stone to ALS Drug Screening Amyotrophic lateral sclerosis (ALS) is an untreatable disorder in which the motor neurons degenerate, resulting in paralysis and death. Induced pluripotent stem cell (iPSC) technology makes it possible to analyze motor neurons from patients with ALS and to use them for screening new candidate drugs. In new work, Egawa et al. obtained motor neurons by inducing differentiation of iPSC lines derived from several patients with familial ALS. These patients carried disease-causing mutations in the gene encoding Tar DNA binding protein-43 (TDP-43). The ALS motor neurons in culture recapitulated cellular and molecular abnormalities associated with ALS. For example, the authors found that mutant TDP-43 in the ALS motor neurons perturbed RNA metabolism and that the motor neurons were more vulnerable to cellular stressors such as arsenite. The researchers then used the ALS motor neurons in a drug screening assay and identified a compound called anacardic acid, a histone acetyltransferase inhibitor, that could reverse some of the ALS phenotypes observed in the motor neurons. The new work provides an encouraging step toward using motor neurons generated from iPSCs derived from ALS patients to learn more about what triggers the death of motor neurons in this disease and to identify new candidate drugs that may be able to slow or reverse the devastating loss of motor neurons. Amyotrophic lateral sclerosis (ALS) is a late-onset, fatal disorder in which the motor neurons degenerate. The discovery of new drugs for treating ALS has been hampered by a lack of access to motor neurons from ALS patients and appropriate disease models. We generate motor neurons from induced pluripotent stem cells (iPSCs) from familial ALS patients, who carry mutations in Tar DNA binding protein-43 (TDP-43). ALS patient–specific iPSC–derived motor neurons formed cytosolic aggregates similar to those seen in postmortem tissue from ALS patients and exhibited shorter neurites as seen in a zebrafish model of ALS. The ALS motor neurons were characterized by increased mutant TDP-43 protein in a detergent-insoluble form bound to a spliceosomal factor SNRPB2. Expression array analyses detected small increases in the expression of genes involved in RNA metabolism and decreases in the expression of genes encoding cytoskeletal proteins. We examined four chemical compounds and found that a histone acetyltransferase inhibitor called anacardic acid rescued the abnormal ALS motor neuron phenotype. These findings suggest that motor neurons generated from ALS patient–derived iPSCs may provide a useful tool for elucidating ALS disease pathogenesis and for screening drug candidates.
Scientific Reports | 2015
Masato Nakagawa; Yukimasa Taniguchi; Sho Senda; Nanako Takizawa; Tomoko Ichisaka; Kanako Asano; Asuka Morizane; Daisuke Doi; Jun Takahashi; Masatoshi Nishizawa; Yoshinori Yoshida; Taro Toyoda; Kenji Osafune; Kiyotoshi Sekiguchi; Shinya Yamanaka
In order to apply human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) to regenerative medicine, the cells should be produced under restricted conditions conforming to GMP guidelines. Since the conventional culture system has some issues that need to be addressed to achieve this goal, we developed a novel culture system. We found that recombinant laminin-511 E8 fragments are useful matrices for maintaining hESCs and hiPSCs when used in combination with a completely xeno-free (Xf) medium, StemFit™. Using this system, hESCs and hiPSCs can be easily and stably passaged by dissociating the cells into single cells for long periods, without any karyotype abnormalities. Human iPSCs could be generated under feeder-free (Ff) and Xf culture systems from human primary fibroblasts and blood cells, and they possessed differentiation abilities. These results indicate that hiPSCs can be generated and maintained under this novel Ff and Xf culture system.
Stem cell reports | 2014
Daisuke Doi; Bumpei Samata; Mitsuko Katsukawa; Tetsuhiro Kikuchi; Asuka Morizane; Yuichi Ono; Kiyotoshi Sekiguchi; Masato Nakagawa; Malin Parmar; Jun Takahashi
Summary Human induced pluripotent stem cells (iPSCs) can provide a promising source of midbrain dopaminergic (DA) neurons for cell replacement therapy for Parkinson’s disease. However, iPSC-derived donor cells inevitably contain tumorigenic or inappropriate cells. Here, we show that human iPSC-derived DA progenitor cells can be efficiently isolated by cell sorting using a floor plate marker, CORIN. We induced DA neurons using scalable culture conditions on human laminin fragment, and the sorted CORIN+ cells expressed the midbrain DA progenitor markers, FOXA2 and LMX1A. When transplanted into 6-OHDA-lesioned rats, the CORIN+ cells survived and differentiated into midbrain DA neurons in vivo, resulting in significant improvement of the motor behavior, without tumor formation. In particular, the CORIN+ cells in a NURR1+ cell-dominant stage exhibited the best survival and function as DA neurons. Our method is a favorable strategy in terms of scalability, safety, and efficiency and may be advantageous for clinical application.
Stem cell reports | 2013
Asuka Morizane; Daisuke Doi; Tetsuhiro Kikuchi; Keisuke Okita; Akitsu Hotta; Toshiyuki Kawasaki; Takuya Hayashi; Hirotaka Onoe; Takashi Shiina; Shinya Yamanaka; Jun Takahashi
Summary Induced pluripotent stem cells (iPSCs) provide the potential for autologous transplantation using cells derived from a patient’s own cells. However, the immunogenicity of iPSCs or their derivatives has been a matter of controversy, and up to now there has been no direct comparison of autologous and allogeneic transplantation in the brains of humans or nonhuman primates. Here, using nonhuman primates, we found that the autologous transplantation of iPSC-derived neurons elicited only a minimal immune response in the brain. In contrast, the allografts caused an acquired immune response with the activation of microglia (IBA-1+/MHC class II+) and the infiltration of leukocytes (CD45+/CD3+). Consequently, a higher number of dopaminergic neurons survived in the autografts. Our results suggest that the autologous transplantation of iPSC-derived neural cells is advantageous for minimizing the immune response in the brain compared with allogeneic grafts.
Stem Cells | 2006
Hitoshi Fukuda; Jun Takahashi; Kiichi Watanabe; Hideki Hayashi; Asuka Morizane; Masaomi Koyanagi; Yoshiki Sasai; Nobuo Hashimoto
The differentiation of dopaminergic (DA) neurons from mouse embryonic stem cells (ESCs) can be efficiently induced, making these neurons a potential source for transplantation as a treatment for Parkinsons disease, a condition characterized by the gradual loss of midbrain DA neurons. One of the major persistent obstacles to the successful implementation of therapeutic ESC transplantation is the propensity of ESC‐derived grafts to form tumors in vivo. To address this problem, we used fluorescence‐activated cell sorting to purify mouse ESC‐derived neural precursors expressing the neural precursor marker Sox1. ESC‐derived, Sox1+ cells began to express neuronal cell markers and differentiated into DA neurons upon transplantation into mouse brains but did not generate tumors in this site. In contrast, Sox1− cells that expressed ESC markers frequently formed tumors in vivo. These results indicate that Sox1‐based cell sorting of neural precursors prevents graft‐derived tumor formation after transplantation, providing a promising strategy for cell transplantation therapy of neurodegenerative disorders.
Journal of Neuroscience Research | 2011
Asuka Morizane; Daisuke Doi; Tetsuhiro Kikuchi; Kaneyasu Nishimura; Jun Takahashi
The balance of bone morphogenic protein (BMP), transforming growth factor‐β (TGFβ)/activin/nodal, and Wnt signals regulates the early lineage segregation of human embryonic stem cells (ESCs). Here we demonstrate that a combination of small‐molecule inhibitors of BMP (Dorsomorphin) and TGFβ/activin/nodal (SB431542) signals promotes highly efficient neural induction from both human ESCs and induced pluripotent stem cells (iPSCs). The combination of small molecules had effects on both cell survival and purity of neural differentiation, under conditions of stromal (PA6) cell coculture and feeder‐free floating aggregation culture, for all seven pluripotent stem cell lines that we studied, including three ESC and four iPSC lines. Small molecule compounds are stable and cost effective, so our findings provide a promising strategy for controlled production of neurons in regenerative medicine.
Proceedings of the National Academy of Sciences of the United States of America | 2013
Michiyo Koyanagi-Aoi; Mari Ohnuki; Kazutoshi Takahashi; Keisuke Okita; Hisashi Noma; Yuka Sawamura; Ito Teramoto; Megumi Narita; Yoshiko Sato; Tomoko Ichisaka; Naoki Amano; Akira Watanabe; Asuka Morizane; Yasuhiro Yamada; Tosiya Sato; Jun Takahashi; Shinya Yamanaka
Significance In the past few years, findings have been controversial in regard to whether human induced pluripotent stem cells (hiPSCs) are distinct from human embryonic stem cells (hESCs) in their molecular signatures and differentiation properties. In this study, hiPSCs and hESCs have overlapping variations in molecular signatures such as RNA expression and DNA methylation. However, some hiPSC clones retained a significant number of undifferentiated cells even after neural differentiation culture and formed teratoma when transplanted into mouse brains. These differentiation-defective hiPSC clones were marked by higher expression levels of several genes, including those expressed from long terminal repeats of specific human endogenous retroviruses. They need to be identified and eliminated prior to applications in regenerative medicine. We examined the gene expression and DNA methylation of 49 human induced pluripotent stem cells (hiPSCs) and 10 human embryonic stem cells and found overlapped variations in gene expression and DNA methylation in the two types of human pluripotent stem cell lines. Comparisons of the in vitro neural differentiation of 40 hiPSCs and 10 human embryonic stem cells showed that seven hiPSC clones retained a significant number of undifferentiated cells even after neural differentiation culture and formed teratoma when transplanted into mouse brains. These differentiation-defective hiPSC clones were marked by higher expression levels of several genes, including those expressed from long terminal repeats of specific human endogenous retroviruses. These data demonstrated a subset of hiPSC lines that have aberrant gene expression and defective potential in neural differentiation, which need to be identified and eliminated before applications in regenerative medicine.
Stem Cells | 2012
Daisuke Doi; Asuka Morizane; Tetsuhiro Kikuchi; Hirotaka Onoe; Takuya Hayashi; Toshiyuki Kawasaki; Makoto Motono; Yoshiki Sasai; Hidemoto Saiki; Masanori Gomi; Tatsuya Yoshikawa; Hideki Hayashi; Mizuya Shinoyama; Mohamed M. Refaat; Hirofumi Suemori; Susumu Miyamoto; Jun Takahashi
For the safe clinical application of embryonic stem cells (ESCs) for neurological diseases, it is critical to evaluate the tumorigenicity and function of human ESC (hESC)‐derived neural cells in primates. We have herein, for the first time, compared the growth and function of hESC‐derived cells with different stages of neural differentiation implanted in the brains of primate models of Parkinsons disease. We herein show that residual undifferentiated cells expressing ESC markers present in the cell preparation can induce tumor formation in the monkey brain. In contrast, a cell preparation matured by 42‐day culture with brain‐derived neurotrophic factor/glial cell line‐derived neurotrophic factor (BDNF/GDNF) treatment did not form tumors and survived as primarily dopaminergic (DA) neurons. In addition, the monkeys with such grafts showed behavioral improvement for at least 12 months. These results support the idea that hESCs, if appropriately matured, can serve as a source for DA neurons without forming any tumors in a primate brain. STEM CELLS 2012;30:935–945